Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.38 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.38 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.38 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.38 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2980586 | 0.83 | LMNA (0.45) | TSHRMAOBSMPD1L3MBTL1PARP15 | |
| SCHEMBL2976229 | 0.83 | SIGMAR1 (0.49) | TSHR | |
| SCHEMBL2981354 | 0.78 | TSHR (0.53) | TSHRSMPD1MAPTGAA | |
| SCHEMBL6841050 | 0.76 | CYP17A1 (0.57) | TSHRL3MBTL1HTR6 | |
| SCHEMBL2969685 | 0.75 | TSHR (0.46) | TSHRGAA | |
| SCHEMBL5704545 | 0.74 | SMPD1 (0.48) | TSHRMAOBSMPD1L3MBTL1PARP15 | |
| SCHEMBL6585008 | 0.74 | FDPS (0.55) | TSHRSMPD1MAPTTRPM5 | |
| SCHEMBL2981348 | 0.72 | TSHR (0.52) | TSHR | |
| SCHEMBL5704535 | 0.72 | MAPT (0.53) | SMPD1MAPTGAA | |
| SCHEMBL2972264 | 0.72 | TSHR (0.49) | TSHRL3MBTL1HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772258-B2 | Agent for treatment of allergic eye disease | NIKKEN CHEMICALS CO., LTD. (JP) | 2010-08-10 | — | — | US | disclosed |
| US-20080306163-A1 | AGENT FOR TREATMENT OF ALLERGIC EYE DISEASE | NIKKEN CHEMICALS CO., LTD. | 2008-12-11 | — | — | US | disclosed |
| EP-0994100-B1 | 3-ANILINO-2-CYCLOALKENONE DERIVATES | NIKKEN CHEMICALS CO LTD (JP) | 2006-08-30 | — | — | EP | disclosed |
| US-20040220227-A1 | Remedies for allergic eye diseases | NIKKEN CHEMICALS CO., LTD. (JP) | 2004-11-04 | — | — | US | disclosed |
| EP-1410795-A1 | REMEDIES FOR ALLERGIC EYE DISEASES | Nikken Chemicals Company, Limited (JP) | 2004-04-21 | — | — | EP | disclosed |
| US-6235736-B1 | ANTIINFLAMMATORY AGENTS | NIKKEN CHEMICALS CO., LTD. (JP) | 2001-05-22 | — | — | US | disclosed |
| EP-0994100-A1 | 3-ANILINO-2-CYCLOALKENONE DERIVATES | Nikken Chemicals Company, Limited (JP) | 2000-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220227-A1 | Remedies for allergic eye diseases | HRH2, HRH1, HRH4 | TSHR 695/4885MAOB 1934/4885SMPD1 1767/4885 |
| US-20080306163-A1 | AGENT FOR TREATMENT OF ALLERGIC EYE DISEASE | HRH4, HRH3, HRH2 | TSHR 299/4885MAOB 1699/4885SMPD1 2398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.